Please login to the form below
Biogen
This page shows the latest Biogen news and features for those working in and with pharma, biotech and healthcare.
Biogen and Eisai’s Alzheimer’s drug receives FDA accelerated approval
Biogen and Eisai’s Leqembi (lecanemab-irmb) has been approved by the US Food and Drug Administration (FDA) under the accelerated approval pathway to treat Alzheimer’s disease. ... Eisai and Biogen have been collaborating on the joint development and
Latest news
-
Biogen and Alcyone Therapeutics partner in deal worth over $50m
Biogen and Alcyone Therapeutics (Alcyone) have entered into a collaboration and licensing agreement to develop Alcyone’s ThecaFlex DRx System (ThecaFlex) to improve patient experience and access to neurological antisense oligonucleotide
-
Biogen and Genentech sign royalty agreement for blood cancer drug glofitamab
Biogen has reached an agreement with Genentech – a member of the Roche group – on the potential commercialisation of the investigational bispecific antibody, glofitamab, as part of the companies’ long-standing collaboration ... Under the terms of
-
Biogen and Eisai’s Alzheimer’s drug shown to slow memory decline in confirmatory study
Biogen and Eisai have reported full results from the successful phase 3 trial of Alzheimer’s disease (AD) drug, lecanemab, marking the first time a treatment has been shown to both
-
Biogen doses first patient with litifilimab in cutaneous lupus erythematosus study
The disease also disproportionately impacts diverse ethno-racial groups, Biogen reported, including African American, Asian, American Indian/Alaskan Native and Hispanic/Latino communities. ... These pro-inflammatory mediators are thought to play a major
-
Biogen and Denali dose first patients with LRRK2 inhibitor in Parkinson’s disease study
Biogen and Denali Therapeutics have begun dosing the first participants in a phase 3 study to evaluate the efficacy and safety profile of BIIB122 (DNL151) in approximately 400 patients with ... Samantha Budd Haeberlein, head of neurodegeneration
More from news
Approximately 186 fully matching, plus 328 partially matching documents found.
Latest Intelligence
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Another example is Biogen’s $800m acquisition of Nightstar’s late-stage gene therapy assets for retinal disease – NSR-REP1 and NSR-RPGR.
-
Switzerland: a life sciences hub
The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others.
-
Alzheimer’s: the search for a cure
The whiplash turnaround is the result of Biogen’s analysis of data from two phase 3 trials. ... Baird analyst Brian Skorney is among the people who have a dim view of Biogen’s prospects.
-
20 for 2020 – Five pharma leaders to watch in 2020
Analysts think the deal could catapult Galapagos into the top tier of biopharma companies, joining the likes of Regeneron, Biogen and Roche’s Genentech unit, providing its pipeline delivers as hoped
-
Great expectations: the urgent need for common purpose in Alzheimer’s disease
Biogen surprised the world last autumn by announcing a re-evaluation of its latest aducanumab trial and the company is now expected to apply for regulatory approval.
More from intelligence
Approximately 2 fully matching, plus 45 partially matching documents found.
Latest appointments
-
BMS appoints new commercial leader, Davies joins Eisai and more
operations. She joins Sobi from Biogen, where she served as vice president for global supply chain operations and strategic partnerships.
-
Biogen appoints executive VP, corporate development
Biogen has appointed Daniel Karp as its executive vice president, corporate development effective 11 June. ... He said: “It's a privilege to join Biogen, a true leader in neuroscience," Karp said.
-
Gamida Cell strengthens leadership team
Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at the company, activities he has practised during his time with Biogen, Amgen and Novartis.
-
Editas Medicine names James Mullen as chairman
Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.
-
Acumen appoints new strategy director
Thomas Bols will focus on reinforcing Acumen’s healthcare practice
More from appointments
Approximately 16 fully matching, plus 32 partially matching documents found.
Latest from PMHub
-
Viseven opens a new center of excellence in India
Biogen. Viseven enables an innovative governance model where a senior specialist is always involved in content production.
-
Mednet Group
Alzheimer’s Research UK. Alzheimer’s Society. Basic Needs. Biogen. Butterfly Scheme. Cardiomyopathy UK.
-
EPG Health
21Grams, Almirall, Alnylam, Amicus Therapeutics, AstraZeneca, Biogen, Boldscience, Caudex, Clinical Thinking, Convatec, CSL Behring, EMD Serono, GSK, Havas Lynx Group, In Vivo Academy, Ipsen, Janssen, Lupus UK, Merck, Novartis, Philips, Pfizer,
-
Article: Market access in Brazil
In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde
-
IGNIFI
Allergan. Biogen. Boehringer Ingelheim. CO.DON. Danone Nutricia. Ferring Pharmaceuticals. GW Pharmaceuticals.
More from PMHub
Approximately 1 fully matching, plus 11 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- Europe’s cancer community publishes new report on transforming patient care
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- EU outlines measures to mitigate antibiotic shortage across Europe
- ASH 2022: bad blood but big advances
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Omnichannel communications in Medical Affairs: closing the gap between aspiration and reality
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Alzheimer’s Society urges UK government to deliver on dementia plan
- Ipsen reports positive phase 3 data for Onivyde in pancreatic cancer
- Sanofi backs vaccines unit with €350m Canadian facility
- World Health Organization releases latest set of COVID-19 guidelines
PMHub
M3 (EU)
M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...
Latest intelligence
- ASH 2022: bad blood but big advances
- Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
